🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Organization SENEX BIOTECHNOLOGY, INC.Location COLUMBIA, UNITED STATESPosted 13 Dec 2024Deadline 30 Nov 2025 ⚠️
NIHUS FederalResearch GrantFY2025Abdominal CavityAnimal ModelAnimal Models and Related StudiesAnoikisAnti-Cancer AgentsAnti-VEGFAnti-VEGF Humanized Monoclonal AntibodyAnti-VEGF RhuMAbAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsBlood PlasmaCDDPCancer DrugCancer ModelCancer PatientCancer TreatmentCancerModelCancersCavitas abdominisCell BodyCell DeathCellsCharacteristicsCis-diammine-dichloroplatinumCis-diamminedichloridoplatinumCis-diamminedichloro Platinum (II)Cis-dichloroammine Platinum (II)Cis-platinous Diamine DichlorideCis-platinum IICis-platinum II Diamine DichlorideCisplatinCisplatinaCisplatinumClinical TrialsControl GroupsCysplatynaCytotoxic agentCytotoxic drugDebulkingDevelopmentDichlorodiammineplatinumDiseaseDisorderDistant CancerDistant MetastasisDoseDrug DeliveryDrug Delivery SystemsDrug KineticsDrug TherapyDrug usageDrugsEnvironmentExcipientsFemale Reproductive CancerFormulationFutureGene ExpressionGene TranscriptionGeneralized GrowthGenetic TranscriptionGoalsGreater sac of peritoneumGrowthGynecologic CancerGynecological CancerHumanHyperthermiaIND FilingIND applicationIND packageIND submissionInorganic Platinum CompoundsIntraperitoneal ChemotherapyIntravenousInvestigational New Drug ApplicationKinasesLengthLytotoxicityMalignant Female Reproductive System NeoplasmMalignant Gynecologic NeoplasmMalignant Gynecologic TumorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant TumorMalignant Tumor of the Female Reproductive SystemMalignant Tumor of the OvaryMalignant neoplasm of ovaryMeasuresMediatorMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsMoAb VEGFModelingModern ManMolecular Tumor SuppressionMonoclonal Antibody Anti-VEGFMurineMusNeoplasm MetastasisNeoplastic Disease Chemotherapeutic AgentsNoduleOmental FatOmentumOralOral AdministrationOral Drug AdministrationOvarian Clear Cell CancerOvarian Clear Cell CarcinomaOvarian Clear Cell NeoplasmOvarian Clear Cell TumorOvary CancerPARP InhibitorPARP-1 inhibitorPARPiPatientsPeritonealPeritoneal CavityPeritoneumPeyrone's ChloridePeyrone's SaltPharmaceutical PreparationsPharmacokineticsPharmacological TreatmentPharmacotherapyPhasePhenotypePhosphotransferase GenePhosphotransferasesPlasmaPlasma SerumPlatinum AgentsPlatinum CompoundsPlatinum DiamminodichloridePoly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) polymerase 1 inhibitorPolymersProcessQOLQuality of lifeRNA ExpressionRNA SeqRNA sequencingRNAseqRecombinant Humanized Anti-VEGF Monoclonal AntibodyRecombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth FactorRelapseResistanceReticuloendothelial System, Serum, PlasmaRhuMAb VEGFSTTRSafetySecondary NeoplasmSecondary TumorSerous AdenocarcinomaSerous CystadenocarcinomaShapesSmall Business Technology Transfer ResearchStomachStructureSurvival AnalysesSurvival AnalysisSurvival RateSuspension substanceSuspensionsTemperatureTestingTissue GrowthToxic effectToxicitiesToxicokineticsTranscriptionTransphosphorylasesTumor BurdenTumor CellTumor DebulkingTumor LoadTumor SuppressionTumor-Specific Treatment Agentsanti-cancer druganti-cancer therapybevacizumabbioluminescence imagingbioluminescent imagingcancer metastasiscancer sub-typescancer subtypescancer therapycancer typecancer-directed therapychemotherapeutic agentchemotherapeutic compoundschemotherapeutic drugschemotherapeutic medicationschemotherapycis dichlorodiammineplatinumcis platinum compoundcis-Diaminedichloroplatinumcis-Diamminedichloroplatinumcis-Diamminedichloroplatinum(II)cis-Dichlorodiammineplatinum(II)cis-Platinumcopolymercytoreductive surgerycytotoxicitydetermine efficacydevelopmentaldrug candidatedrug interventiondrug treatmentdrug usedrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy testingevaluate efficacyexamine efficacygastricgynecologic malignancygynecological malignancyimprovedinhibitorinhibitor druginhibitor therapeuticinhibitor therapyintraoral drug deliveryintraperitonealintraperitoneal therapykinase inhibitormalignancymalignant ascitesmanufacturemodel of animalmouse modelmurine modelnanonano particlenano particle deliverynano-sized particlenanoparticlenanoparticle deliverednanoparticle deliverynanosized particlenecrocytosisneoplasm/cancerneoplastic cellnew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetontogenyovarian cancerpharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspolymerpolymericpotential biological markerpotential biomarkerpreventpreventingprogramsresistantresponseresponse biomarkerresponse markersrhuMabVEGFsafety studyscale upsmall molecular inhibitorsmall molecule inhibitorstandard of caresurgical cytoreductionsystemic toxicitytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttaxanetranscriptional reprogrammingtranscriptome sequencingtranscriptomic sequencingtranscriptomicstumortumor cell metastasistumor cytoreduction
Applications closed.
Description preview
Metastatic ovarian cancers (OC), the second most common gynecological malignancy, is a lethal disease, the
treatment of which still relies primarily on conventional cytotoxic drugs. Metastatic OC in most patients is localized
to the peritoneal cavity, including the peritoneum and omentum along with malignant ascites, making this cancer
the primary…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click